Voltar
Revisão Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups

2012; BioMed Central; Volume: 12; Issue: 1 Linguagem: Inglês

10.1186/1471-2407-12-89

ISSN

1471-2407

Autores

Lígia Traldi Macedo, André Bacellar Costa Lima, André Deeke Sasse,

Tópico(s)

Cancer Treatment and Pharmacology

Resumo

Bevacizumab has an important role in first-line treatment of metastatic colorectal cancer. However, clinical trials studying its effect have involved distinct chemotherapy regimens with divergent results. The aim of this meta-analysis is to gather current data and evaluate not only the efficacy of bevacizumab, but also the impact of divergent backbone regimens.

Referência(s)